AN2 Therapeutics (ANTX) Cash from Financing Activities (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly Cash from Financing Activities of $37.3 million for Q1 2026, up 57329.23% year-over-year from N/an in Q1 2025, and up 77668.75% quarter-over-quarter from $48000.0 in Q3 2025.
Powered by 
Analysis
AN2 Therapeutics (ANTX) Cash from Financing Activities (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Cash from Financing Activities for 6 consecutive years, with $37.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 57329.23% year-over-year to $37.3 million; the TTM figure through Mar 2026 stood at $37.4 million (up 42373.86% YoY), while the FY2025 annual figure was $113000.0, down 69.62% from the prior year.
- Cash from Financing Activities improved to $37.3 million in Q1 2026 per ANTX's latest filing, from $48000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $66.1 million in Q3 2023 and bottomed at -$321000.0 in Q4 2023.
- Historically, Cash from Financing Activities has averaged $16.1 million across 5 years, with a median of $274000.0 in 2023.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 660760.0% — and 2024, when it sank 99.97%.
- AN2 Therapeutics' Cash from Financing Activities stood at -$10000.0 in 2022, then slumped by 3110.0% to -$321000.0 in 2023, then surged by 107.17% to $23000.0 in 2024, then soared by 108.7% to $48000.0 in 2025, then surged by 77668.75% to $37.3 million in 2026.
- Business Quant data shows ANTX's Cash from Financing Activities at $37.3 million in Q1 2026, $48000.0 in Q3 2025, and $65000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - | 1.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.49 Mn |
| Mar 31, 2026 | 37.33 Mn |
| Sep 30, 2025 | 48,000.00 |
| Mar 31, 2025 | 65,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Mar 31, 2024 | 349,000.00 |
| Dec 31, 2023 | -321,000.00 |
| Sep 30, 2023 | 66.07 Mn |
| Jun 30, 2023 | 19.05 Mn |
| Mar 31, 2023 | 199,000.00 |
| Sep 30, 2022 | -10,000.00 |
| Jun 30, 2022 | 7.18 Mn |
| Mar 31, 2022 | 63.19 Mn |
| Dec 31, 2021 | -969,000.00 |
| Sep 30, 2021 | -240,000.00 |
| Mar 31, 2021 | 79.74 Mn |